Nowatzky Johannes, Manches Olivier
Department of Medicine, Division of Rheumatology, New York University School of Medicine;
Immunobiology and Immunotherapy in Chronic Diseases, Institute for Advanced Biosciences, Université Grenoble Alpes, Inserm U1209/CNRS UMR 5309; Etablissement Français du Sang Auvergne-Rhône-Alpes.
J Vis Exp. 2020 May 17(159). doi: 10.3791/61075.
Human regulatory T cells (Treg) are notoriously difficult to isolate in high purity given the current methods of Treg enrichment. These methods are based on the identification of Treg through several activation-dependent cellular surface markers with varying expression levels in different physiologic and pathologic conditions. Populations isolated as "Treg" therefore often contain considerable numbers of non-Treg effector cells (i.e., Teff) which hamper the precise phenotypic and functional characterization of these cells, their genomic and proteomic characterization, their reliable enumeration in different states of health and disease, as well as their isolation and expansion for therapeutic purposes. The latter, in particular, remains a major hurdle, as the inadvertent expansion of effector cells homing in Treg-relevant cellular compartments (e.g., CD4CD25 T cells) may render Treg-based immunotherapy ineffective, or even harmful. This work presents a method that circumvents the problems associated with population-based isolation and expansion of Treg and shows that the generation of Treg candidate clones with the subsequent selection, culture, and expansion of only carefully vetted, monoclonal cells, enables the generation of an ultrapure Treg cell product that can be kept in culture for many months, enabling downstream investigation of these cells, including for possible therapeutic applications.
鉴于目前调节性T细胞(Treg)的富集方法,人类调节性T细胞极难被高纯度分离。这些方法是基于通过几种依赖激活的细胞表面标志物来识别Treg,这些标志物在不同的生理和病理条件下表达水平各异。因此,被分离为“Treg”的细胞群体通常包含相当数量的非Treg效应细胞(即Teff),这妨碍了对这些细胞进行精确的表型和功能表征、基因组和蛋白质组表征、在不同健康和疾病状态下的可靠计数,以及为治疗目的进行的分离和扩增。尤其是后者,仍然是一个主要障碍,因为归巢于Treg相关细胞区室(如CD4CD25 T细胞)的效应细胞的意外扩增可能会使基于Treg的免疫疗法无效,甚至有害。这项工作提出了一种方法,可规避与基于群体的Treg分离和扩增相关的问题,并表明通过生成Treg候选克隆,随后仅对经过仔细筛选的单克隆细胞进行选择、培养和扩增,能够生成一种超纯的Treg细胞产品,该产品可在培养中保存数月,从而能够对这些细胞进行下游研究,包括可能的治疗应用。